Navigation Links
Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth
Date:2/12/2009

rge and pioneering international drug development contract research organization); Vice President of Biosciences at SRI International (management of 180 scientists and staff), Vice President of Research for ILEX Oncology, a NASDAQ listed company, (acquired by Genzyme for $1B) and CEO and founder of Convergence Pharmaceuticals (acquired by ILEX). He has also co-founded the Critical Path Institute (a not for profit focused on regulatory innovation in Tucson AZ), EmergingMed, Inc. (a web based clinical trial prequalification and management service), and was part of the initial founding management of Cytokine Networks, Inc. Dr. Rice is currently an inventor on over 20 patents or patent applications and has authored over 75 manuscripts and book chapters.

Mr. Duggan commented, "Pharmacyclics has already benefitted greatly from Glenn's extensive biotechnology research and product development background that includes oncology, inflammation, neurobiology and cardiovascular diseases. Glenn's experience in regulatory affairs, international business development and fundraising will be an added plus as we evaluate opportunities to grow our business."

Dr. Maky Zanganeh has been previously appointed as Vice President of Business Development for Pharmacyclics. Dr. Zanganeh most recently accepted a position as Director General for the French government initiative biocluster project in France. Prior to that she served as Vice President of Business Development for Robert Duggan & Associates. From 1998 to 2003, Dr. Zanganeh was worldwide President Director General for Europe, Middle East and Africa and also became Vice President of Training & Education for Computer Motion Inc., the world initiator of medical robotics. Dr. Zanganeh received her degree from Louis Pasteur University in Strasbourg, France and her MBA from Schiller International University in France. She is fluent in French, German, Persian & Englis
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Pharmacyclics Secures $5.0 Million in Debt Financing
2. Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
3. Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
4. Pharmacyclics Announces It Received Nasdaq Notice of Compliance
5. Pharmacyclics Announces It Received Nasdaq Notification
6. Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
7. Savient Announces Appointment of David Gionco as Chief Financial Officer
8. Vermillion Announces Notice of Issuance of U.S. Patent Covering Hepcidin as a Biomarker for Ovarian Cancer
9. SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS
10. Genesis Pharmaceuticals Announces Conference Call to Discuss Results for its Second Quarter of FY 2009
11. Cord Blood Announces $1 Million Reduction in Long Term Debt
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2013)... The JM Internet Group (web: jm-seo.org), ... proudly announced that the company's YouTube channel on ... views on YouTube. The company uses YouTube as a ... and training for small businesses with much success. , ... tips helpful for their SEO strategies", explained Jason McDonald, ...
(Date:5/17/2013)... transplant rejection occurs when the transplant recipient,s immune system ... it. It was previously thought that T cells, the ... by molecules known as chemokines in order to migrate ... Journal of Clinical Investigation , Fadi Lakkis and ... demonstrate that chemokine stimulation of T cells is not ...
(Date:5/17/2013)... TRIANGLE PARK, N.C., USA (PRWEB) May 17, 2013 ...     Green Globes Certified for sustainability , ... and insect pressures , Syngenta ... opening celebration today at the company’s RTP Innovation Center. ... Lab allows company researchers to simulate any agricultural climate ...
(Date:5/17/2013)... May 17, 2013 /PRNewswire-iReach/ -- Aridis is pleased ... with Switzerland -based Kenta Biotech ... monoclonal antibody (mAb) products, and technologies. This asset ... for treatment of infections by common pathogens including ... , Pseudomonas aeruginosa , Acinetobacter baumannii ...
Breaking Biology Technology:YouTube Channel on SEO Tips Surpasses 175,000 Views, Announces JM Internet Group 2Syngenta Opens Unique $72 Million Advanced Crop Lab 2Syngenta Opens Unique $72 Million Advanced Crop Lab 3Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 3
... 11 Friendly LRL Holdings LLC ("FLH") today announced that ... of the outstanding shares of common stock of Startech Environmental ... offer was scheduled to expire at 11:59 pm, New York ... previously tendered pursuant to the tender offer and not withdrawn ...
... PARIS, September 11 Novexel, a specialty pharmaceutical,company ... antibiotics,designed to overcome the significant global problem of ... subject of 16 posters and one slide,presentation at ... on,Antimicrobial Agents and Chemotherapy (ICAAC). The ICAAC meeting, ...
... 10 Bioheart, Inc., (OTC Bulletin Board: BHRT) a company ... diagnose and treat heart failure and other cardiovascular diseases announced ... development has been invited to participate in the 2009 World ... , Ms. Comella will speak on the concurrent ...
Cached Biology Technology:Friendly LRL Holdings Terminates Offer To Acquire Startech Environmental Corporation 2Friendly LRL Holdings Terminates Offer To Acquire Startech Environmental Corporation 3Novexel Presents 16 Posters and one Slide Presentation at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Meeting in San Francisco 2Novexel Presents 16 Posters and one Slide Presentation at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Meeting in San Francisco 3Novexel Presents 16 Posters and one Slide Presentation at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Meeting in San Francisco 4Novexel Presents 16 Posters and one Slide Presentation at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Meeting in San Francisco 5Bioheart Inc. to Participate in the 2009 World Stem Cell Summit on September 23rd 2Bioheart Inc. to Participate in the 2009 World Stem Cell Summit on September 23rd 3
(Date:5/18/2013)... 18, 2013) Research presented today at Digestive Disease ... with findings about the impact of coffee on autoimmune ... While coffee consumption recently has been associated with reduced ... a few more cups of java each month also ... disease. Researchers at the Mayo Clinic, Rochester, MN, linked ...
(Date:5/17/2013)... day, insects provide the white noise of the South, but ... year, the Southern air hangs heavy from the humidity and ... more than 140 species of frogs, toads and salamanders, is ... the ponds and swamps are the auditorium for their symphonic ... and Monitoring Initiative, or ARMI, have front-row seats. ...
(Date:5/17/2013)... 2013, Shenzhen, China---- Why Tibetan antelope can live ... In a collaborative research published in Nature ... other institutes provide evidence that some genetic factors ... harsh highland environments. The data in this work ... mechanisms and the biology of other ruminant species. ...
Breaking Biology News(10 mins):Coffee consumption associated with reduced risk of autoimmune liver disease 2Front-row seats to climate change 2Front-row seats to climate change 3Front-row seats to climate change 4The genome sequence of Tibetan antelope sheds new light on high-altitude adaptation 2
... pieces of DNA in 100 small fish have opened ... technologies, researchers now know many of the genomic regions ... water in several independently evolved populations. The discovery ... National Science Foundation and National Institutes of Health -- ...
... HOUSTON, Feb. 25, 2010 Just weeks into his ... chair of the University of Houston,s new department of ... He was selected and recently inducted into ... Association for the Advancement of Science (AAAS) and the ...
... a paradox that,s puzzled scientists for a half-century. ... depends on those species responding differently to the availability ... species draw a blank? Competitors like black gums ... shaded understories of eastern U.S. forests, yet species-level data ...
Cached Biology News:Stickleback genomes shining bright light on evolution 2Stickleback genomes shining bright light on evolution 3New biomedical engineering chair earns high honors 2New biomedical engineering chair earns high honors 3Forest tree species diversity depends on individual variation 2Forest tree species diversity depends on individual variation 3
... product contains 5 ml of DETACHaBEAD ... from Dynabeads CD19 (Pan B). ... (Pan B) and released with DETACHaBEAD ... Cells are suitable for applications such ...
This Malachite Green Phosphate Detection Kit...
5-bromo-4-chloro-3-indolyl b -D-galactopyranoside (X-Gal)...
...
Biology Products: